Effects of chlorhexidine gluconate oral care on hospital mortality: a hospital-wide, observational cohort study

Mieke Deschepper, Willem Waegeman, Kristof Eeckloo, Dirk Vogelaers, Stijn Blot, Mieke Deschepper, Willem Waegeman, Kristof Eeckloo, Dirk Vogelaers, Stijn Blot

Abstract

Purpose: Chlorhexidine oral care is widely used in critically and non-critically ill hospitalized patients to maintain oral health. We investigated the effect of chlorhexidine oral care on mortality in a general hospitalized population.

Methods: In this single-center, retrospective, hospital-wide, observational cohort study we included adult hospitalized patients (2012-2014). Mortality associated with chlorhexidine oral care was assessed by logistic regression analysis. A threshold cumulative dose of 300 mg served as a dichotomic proxy for chlorhexidine exposure. We adjusted for demographics, diagnostic category, and risk of mortality expressed in four categories (minor, moderate, major, and extreme).

Results: The study cohort included 82,274 patients of which 11,133 (14%) received chlorhexidine oral care. Low-level exposure to chlorhexidine oral care (≤ 300 mg) was associated with increased risk of death [odds ratio (OR) 2.61; 95% confidence interval (CI) 2.32-2.92]. This association was stronger among patients with a lower risk of death: OR 5.50 (95% CI 4.51-6.71) with minor/moderate risk, OR 2.33 (95% CI 1.96-2.78) with a major risk, and a not significant OR 1.13 (95% CI 0.90-1.41) with an extreme risk of mortality. Similar observations were made for high-level exposure (> 300 mg). No harmful effect was observed in ventilated and non-ventilated ICU patients. Increased risk of death was observed in patients who did not receive mechanical ventilation and were not admitted to ICUs. The adjusted number of patients needed to be exposed to result in one additional fatality case was 47.1 (95% CI 45.2-49.1).

Conclusions: These data argue against the indiscriminate widespread use of chlorhexidine oral care in hospitalized patients, in the absence of proven benefit in specific populations.

Keywords: Chlorhexidine oral care; In-hospital mortality; Risk of mortality.

Conflict of interest statement

Conflicts of interest

All authors declare that there are no potential conflicts of interest to disclose.

Compliance with Ethics Guidelines

The study was approved by the ethics committee at Ghent University Hospital (Belgian registration no. B670201731386).

References

    1. Melsen WG, Rovers MM, Bonten MJM. Ventilator-associated pneumonia and mortality: a systematic review of observational studies. Crit Care Med. 2009;37:2709–2718.
    1. Muscedere JG, Martin CM, Heyland DK. The impact of ventilator-associated pneumonia on the Canadian health care system. J Crit Care. 2008;23:5–10. doi: 10.1016/j.jcrc.2007.11.012.
    1. Blot S, Koulenti D, Dimopoulos G, et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. Crit Care Med. 2014;42:601–609. doi: 10.1097/01.ccm.0000435665.07446.50.
    1. Lorente L, Blot S, Rello J. Evidence on measures for the prevention of ventilator-associated pneumonia. Eur Respir J. 2007;30:1193–1207. doi: 10.1183/09031936.00048507.
    1. Lorente L, Blot S, Rello J. New issues and controversies in the prevention of ventilator-associated pneumonia. Am J Respir Crit Care Med. 2010;182:870–876. doi: 10.1164/rccm.201001-0081CI.
    1. Blot SI, Poelaert J, Kollef M. How to avoid microaspiration? A key element for the prevention of ventilator-associated pneumonia in intubated ICU patients. BMC Infect Dis. 2014;14:119. doi: 10.1186/1471-2334-14-119.
    1. Nseir S, Lorente L, Ferrer M, et al. Continuous control of tracheal cuff pressure for VAP prevention: a collaborative meta-analysis of individual participant data. Ann Intensive Care. 2015;5:43. doi: 10.1186/s13613-015-0087-3.
    1. Maertens B, Blot K, Blot S. Prevention of ventilator-associated and early postoperative pneumonia through tapered endotracheal tube cuffs: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2018;46:316–323. doi: 10.1097/CCM.0000000000002889.
    1. Labeau SO, Van de Vyver K, Brusselaers N, et al. Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis. Lancet Infect Dis. 2011;11:845–854. doi: 10.1016/S1473-3099(11)70127-X.
    1. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416. doi: 10.1164/rccm.200405-644ST.
    1. Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention (US) Guidelines for preventing health-care-associated pneumonia, 2003 recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. Respir Care. 2004;49:926–939.
    1. Institute for Healthcare Improvement (2012) How-to guide: prevent ventilator-associated pneumonia. Institute for Healthcare Improvement, Cambridge
    1. Mohr NM, Pelaez Gil CA, Harland KK, et al. Prehospital oral chlorhexidine does not reduce the rate of ventilator-associated pneumonia among critically ill trauma patients: a prospective concurrent-control study. J Crit Care. 2015;30:787–792. doi: 10.1016/j.jcrc.2015.03.017.
    1. Hollaar V, van der Maarel-Wierink C, van der Putten G-J, et al. Effect of daily application of a 0.05% chlorhexidine solution on the incidence of (aspiration) pneumonia in care home residents: design of a multicentre cluster randomised controlled clinical trial. BMJ Open. 2015;5:e007889. doi: 10.1136/bmjopen-2015-007889.
    1. Sharif-Abdullah SSB, Chong MC, Surindar-Kaur SS, et al. The effect of chlorhexidine in reducing oral colonisation in geriatric patients: a randomised controlled trial. Singap Med J. 2016;57:262–266. doi: 10.11622/smedj.2016091.
    1. Klompas M, Speck K, Howell MD, et al. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis. JAMA Intern Med. 2014;174:751–761. doi: 10.1001/jamainternmed.2014.359.
    1. Price R, MacLennan G, Glen J, SuDDICU Collaboration Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ. 2014;348:g2197–g2197. doi: 10.1136/bmj.g2197.
    1. Klompas M, Li L, Kleinman K, et al. Associations between ventilator bundle components and outcomes. JAMA Intern Med. 2016;176:1277–1283. doi: 10.1001/jamainternmed.2016.2427.
    1. Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT) Eur Respir J. 2017;50:1700582. doi: 10.1183/13993003.00582-2017.
    1. Centers for Disease Control and Prevention (2011) National Center for Health Statistics. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). . Accessed 24 May 2017
    1. 3M Health Information Systems (2003) All Patient Refined Diagnosis Related Groups (APR-DRGs), Version 20.0, methodology overview. . Accessed 23 May 2017
    1. Iezzoni LI, Ash AS, Shwartz M, et al. Predicting who dies depends on how severity is measured: implications for evaluating patient outcomes. Ann Intern Med. 1995;123:763–770. doi: 10.7326/0003-4819-123-10-199511150-00004.
    1. Messina G, Forni S, Collini F, et al. Short-term adjusted outcomes for heart failure. Heart Int. 2015;10:e1–e5. doi: 10.5301/heartint.5000220.
    1. De Marco MF, Lorenzoni L, Addari P, Nante N. Evaluation of the capacity of the APR-DRG classification system to predict hospital mortality. Epidemiol Prev. 2002;26:183–190.
    1. Baram D, Daroowalla F, Garcia R, et al. Use of the All Patient Refined-Diagnosis Related Group (APR-DRG) risk of mortality score as a severity adjustor in the medical ICU. Clin Med Circ Respir Pulm Med. 2008;2:19–25.
    1. Bender R, Blettner M. Calculating the “number needed to be exposed” with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol. 2002;55:525–530. doi: 10.1016/S0895-4356(01)00510-8.
    1. Plantinga NL, Wittekamp BHJ, Leleu K, et al. Oral mucosal adverse events with chlorhexidine 2% mouthwash in ICU. Intensive Care Med. 2016;42:620–621. doi: 10.1007/s00134-016-4217-7.
    1. Zand F, Zahed L, Mansouri P, et al. The effects of oral rinse with 0.2% and 2% chlorhexidine on oropharyngeal colonization and ventilator associated pneumonia in adults’ intensive care units. J Crit Care. 2017
    1. Hirata K, Kurokawa A. Chlorhexidine gluconate ingestion resulting in fatal respiratory distress syndrome. Vet Hum Toxicol. 2002;44:89–91.
    1. Xue Y, Zhang S, Yang Y, et al. Acute pulmonary toxic effects of chlorhexidine (CHX) following an intratracheal instillation in rats. Hum Exp Toxicol. 2011;30:1795–1803. doi: 10.1177/0960327111400104.
    1. Stephens R, Mythen M, Kallis P, et al. Two episodes of life-threatening anaphylaxis in the same patient to a chlorhexidine-sulphadiazine-coated central venous catheter. Br J Anaesth. 2001;87:306–308. doi: 10.1093/bja/87.2.306.
    1. Jee R, Nel L, Gnanakumaran G, et al. Four cases of anaphylaxis to chlorhexidine impregnated central venous catheters: a case cluster or the tip of the iceberg? Br J Anaesth. 2009;103:614–615. doi: 10.1093/bja/aep248.
    1. Parkes AW, Harper N, Herwadkar A, Pumphrey R. Anaphylaxis to the chlorhexidine component of Instillagel: a case series. Br J Anaesth. 2009;102:65–68. doi: 10.1093/bja/aen324.
    1. Tuon FF, Gavrilko O, de Almeida S, et al. Prospective, randomised, controlled study evaluating early modification of oral microbiota following admission to the intensive care unit and oral hygiene with chlorhexidine. J Glob Antimicrob Resist. 2017;8:159–163. doi: 10.1016/j.jgar.2016.12.007.
    1. Sampaio-Maia B, Caldas IM, Pereira ML, et al. The oral microbiome in health and its implication in oral and systemic diseases. Adv Appl Microbiol. 2016;97:171–210. doi: 10.1016/bs.aambs.2016.08.002.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner